These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9738984)

  • 21. The usefulness of a continuous administration of tirapazamine combined with reduced dose-rate irradiation using {gamma}-rays or reactor thermal neutrons.
    Masunaga S; Sakurai Y; Nagata K; Suzuki M; Maruhashi A; Kinashi Y; Nagasawa H; Uto Y; Hori H; Ono K
    Br J Radiol; 2006 Dec; 79(948):991-8. PubMed ID: 16916808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the p53 status of the tumor cells on the effect of reactor neutron beam irradiation, with emphasis on the response of intratumor quiescent cells.
    Masunaga S; Ono K; Takahashi A; Sakurai Y; Ohnishi K; Kobayashi T; Kinashi Y; Takagaki M; Ohnishi T
    Jpn J Cancer Res; 2002 Dec; 93(12):1366-77. PubMed ID: 12495477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repair of potentially lethal damage by total and quiescent cells in solid tumors following a neutron capture reaction.
    Masunaga S; Ono K; Suzuki M; Sakurai Y; Takagaki M; Kobayashi T; Kinashi Y; Akaboshi M
    J Cancer Res Clin Oncol; 1999 Nov; 125(11):609-14. PubMed ID: 10541967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of bioreductive agents, tirapazamine and mitomycin C, on quiescent cell populations in solid tumors, evaluated by micronucleus assay.
    Masunaga S; Ono K; Hori H; Shibata T; Suzuki M; Kinashi Y; Takagaki M; Akaboshi M
    Jpn J Cancer Res; 1997 Sep; 88(9):907-14. PubMed ID: 9369940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentially lethal damage repair by total and quiescent tumor cells following various DNA-damaging treatments.
    Masunaga S; Ono K; Hori H; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y
    Radiat Med; 1999; 17(4):259-64. PubMed ID: 10510897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in the sensitivity of intratumor cells during fractionated tirapazamine administration.
    Masunaga S; Ono K; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y; Hori H
    Jpn J Cancer Res; 2000 Jul; 91(7):731-6. PubMed ID: 10920281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Change in oxygenation status in intratumour total and quiescent cells following gamma-ray irradiation, tirapazamine administration, cisplatin injection and bleomycin treatment.
    Masunaga S; Ono K; Hori H; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y
    Br J Radiol; 2000 Sep; 73(873):978-86. PubMed ID: 11064652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy.
    Ono K; Masunaga SI; Kinashi Y; Takagaki M; Akaboshi M; Kobayashi T; Akuta K
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1081-6. PubMed ID: 8600091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the potential of hexamethylenetetramine, compared with tirapazamine, as a combined agent with {gamma}-irradiation and cisplatin treatment in vivo.
    Masunaga S; Tano K; Watanabe M; Kashino G; Suzuki M; Kinashi Y; Ono K; Nakamura J
    Br J Radiol; 2009 May; 82(977):392-400. PubMed ID: 19153181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The usefulness of mild temperature hyperthermia combined with continuous tirapazamine administration under reduced dose-rate irradiation with gamma-rays.
    Masunaga S; Nagasawa H; Uto Y; Hori H; Nagata K; Suzuki M; Kashino G; Kinashi Y; Ono K
    Int J Hyperthermia; 2007 Feb; 23(1):29-35. PubMed ID: 17575721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of TP53 status of tumor cells including the type and the concentration of administered 10B delivery agents on compound biological effectiveness in boron neutron capture therapy.
    Masunaga SI; Sanada Y; Takata T; Tanaka H; Sakurai Y; Suzuki M; Kirihata M; Ono K
    J Radiat Res; 2023 Mar; 64(2):399-411. PubMed ID: 36763853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combined effect of boronophenylalanine and borocaptate in boron neutron capture therapy for SCCVII tumors in mice.
    Ono K; Masunaga S; Suzuki M; Kinashi Y; Takagaki M; Akaboshi M
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):431-6. PubMed ID: 10030272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
    Masunaga S; Nagasawa H; Uto Y; Hori H; Suzuki M; Nagata K; Kinashi Y; Ono K
    Int J Hyperthermia; 2005 Jun; 21(4):305-18. PubMed ID: 16019857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of employing a ¹⁰B-carrier and manipulating intratumour hypoxia on local tumour response and lung metastatic potential in boron neutron capture therapy.
    Masunaga S; Sakurai Y; Tanaka H; Suzuki M; Liu Y; Kondo N; Maruhashi A; Kinashi Y; Ono K
    Br J Radiol; 2012 Mar; 85(1011):249-58. PubMed ID: 22391496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells.
    Masunaga S; Nagasawa H; Nagata K; Suzuki M; Uto Y; Hori H; Kinashi Y; Ono K
    J Cancer Res Clin Oncol; 2007 Jan; 133(1):47-55. PubMed ID: 16924543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
    Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
    Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of electroporation on cell killing by boron neutron capture therapy using borocaptate sodium (10B-BSH).
    Ono K; Kinashi Y; Masunaga S; Suzuki M; Takagaki M
    Jpn J Cancer Res; 1998 Dec; 89(12):1352-7. PubMed ID: 10081497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delivery of (10)boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy.
    Obayashi S; Kato I; Ono K; Masunaga S; Suzuki M; Nagata K; Sakurai Y; Yura Y
    Oral Oncol; 2004 May; 40(5):474-82. PubMed ID: 15006618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
    Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of bevacizumab combined with boron neutron capture therapy on local tumor response and lung metastasis.
    Masunaga SI; Sakurai Y; Tano K; Tanaka H; Suzuki M; Kondo N; Narabayashi M; Watanabe T; Nakagawa Y; Maruhashi A; Ono K
    Exp Ther Med; 2014 Jul; 8(1):291-301. PubMed ID: 24944637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.